Atomo Diagnostics Ltd. (AT1) Share Price & Analysis

10 Followers

AT1 Stock Chart & Stats

A$0.01A$0.00(8.33%)

At close: Nov 11 4:00 PM GMT+11

Day’s Range: AUD 0.01 - AUD 0.01
52-Week Range: AUD 0.01 - AUD 0.05
Previous Close: AUD 0.01
Volume: N/A
Average Volume (3M): 2.36M
Market Cap: AUD 10.83M
Enterprise Value: AUD 11.18M
Total Cash (Recent Filing): AUD 3.71M
Total Debt (Recent Filing): AUD 373.08K
Price to Earnings (P/E): ―
Beta: 0.57
Next Earnings: Feb 24, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound

The FY2026 revenue rebound indicates renewed demand for Atomo’s rapid diagnostic device platforms after weaker prior periods. If this growth is sustained through customer orders and product adoption, it can improve operating leverage and provide a stronger base for future commercial scale.

Low Leverage

Minimal leverage reduces refinancing exposure and limits interest-related pressure on future cash flows. This gives Atomo greater financial flexibility to support product development, customer programs, and commercial expansion while avoiding the additional constraints associated with a heavily indebted balance sheet.

Narrowing Losses

The materially smaller net loss suggests some progress in cost control and operational discipline, even though profitability has not been reached. Continued improvement could reduce the resources consumed by losses and move the company closer to a sustainable earnings profile over coming periods.

Bears Say

Negative Gross Margin

A negative gross margin means FY2026 product revenue did not cover the reported cost base, undermining the economics of the company’s core offering. Unless pricing, product mix, production costs, or inventory impacts improve, revenue growth may not translate into durable gross-profit expansion.

Persistent Cash Burn

Consistently negative operating and free cash flow shows that Atomo has not yet demonstrated self-funded operations. Even with less severe cash burn in FY2025–FY2026, continued consumption can increase dependence on available funding and limit the company’s ability to invest through an extended period of losses.

Eroding Equity Base

Declining shareholder equity reflects the cumulative effect of ongoing losses and reduces the financial cushion available to absorb further underperformance. Persistently negative returns also indicate that the capital base is not currently generating attractive economic returns, weakening long-term balance-sheet resilience.

Atomo Diagnostics Ltd. News

Atomo Diagnostics Releases CEO Address for 2026 AGM

The latest announcement is out from Atomo Diagnostics Ltd. ( ($AU:AT1) ). Atomo Diagnostics operates in the medical diagnostics sector, although the announcement does not provide details about its products

1w agoAT1

Atomo Diagnostics Reports Strong HIV Growth Amid Operational Transition

Atomo Diagnostics Ltd. ( ($AU:AT1) ) just unveiled an announcement. Atomo Diagnostics, which develops blood-based rapid tests for professional and self-testing, described the past year as transitional amid volatility in

1w agoAT1

Atomo Diagnostics Issues Cautious Q1 2027 Results Overview

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has shared an update. Atomo Diagnostics has released an overview of its first quarter 2027 results, accompanied by extensive disclaimers that frame the material

2w agoAT1

Atomo boosts HIV and syphilis test pipeline as Q1 revenue surges 140%

The latest update is out from Atomo Diagnostics Ltd. ( ($AU:AT1) ). Atomo Diagnostics has expanded its proprietary rapid-testing pipeline through a new memorandum of understanding with Innovation Scientific to

2w agoAT1

Atomo Diagnostics Strikes Deal to Develop Generation 4 HIV Rapid Test

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has issued an announcement. Atomo Diagnostics has signed a Memorandum of Understanding with Innovation Scientific to develop and commercialise a Generation 4 HIV rapid

2w agoAT1

Atomo Diagnostics Updates Timing for Q1 FY27 Investor Webinar

Atomo Diagnostics Ltd. ( ($AU:AT1) ) just unveiled an announcement. Atomo Diagnostics has rescheduled the start time of its Q1 FY27 quarterly investor webinar to 2 p.m. AEDT on 3

2w agoAT1

Atomo Diagnostics Options Lapse, Tidying Up Capital Structure

Atomo Diagnostics Ltd. ( ($AU:AT1) ) just unveiled an update. Atomo Diagnostics has reported the cessation of 275,000 listed options (AT1AO) that expired on 22 August 2026 without being exercised

2w agoAT1

Atomo Diagnostics Options Lapse, Streamlining Capital Structure

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has shared an announcement. Atomo Diagnostics has confirmed that 2,120,000 options, exercisable at $0.035 and due to expire on 1 July 2027, have ceased

2w agoAT1

Atomo Diagnostics Schedules Q1 FY27 Investor Webinar to Boost Stakeholder Engagement

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has provided an update. Atomo Diagnostics has announced a Q1 FY27 quarterly investor webinar to be held on 3 November 2026, hosted by CEO

2w agoAT1

Atomo Diagnostics Sets Virtual AGM for 5 November 2026

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has shared an update. Atomo Diagnostics Limited has called its Annual General Meeting for 5 November 2026, to be held virtually via a Zoom

1M agoAT1

AT1 FAQ

What was Atomo Diagnostics Ltd.’s price range in the past 12 months?

Atomo Diagnostics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.

What is Atomo Diagnostics Ltd.’s market cap?

Atomo Diagnostics Ltd.’s market cap is AU$10.83M.

When is Atomo Diagnostics Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Atomo Diagnostics Ltd.’s earnings last quarter?

Atomo Diagnostics Ltd. released its earnings results on Aug 30, 2026. The company reported -AU$0.002 earnings per share for the quarter.

Is Atomo Diagnostics Ltd. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Atomo Diagnostics Ltd. pay dividends?

Atomo Diagnostics Ltd. does not currently pay dividends.

What is Atomo Diagnostics Ltd.’s EPS estimate?

Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Atomo Diagnostics Ltd. have?

Atomo Diagnostics Ltd. has 902,432,860 shares outstanding.

What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?

Atomo Diagnostics Ltd. reported an EPS of -AU$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?

Currently, no hedge funds are holding shares in AU:AT1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Atomo Diagnostics Ltd. Stock Smart Score

Underperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description